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Two hundred years have passed since Edward Jenner 
first tested a vaccine for the prevention of smallpox and 
established the basic principle of immunization. It was 
an incredible discovery with long-lasting and profound 
implications. In the ensuing period, scientific knowl- 
edge has increased explosively, yet the rationale behind 
Jenner’s approach is still applicable to research on immu- 
nization. 
We now have vaccines for preventing many of the 
major plagues of humanity. We have actually eliminated 
the virus that was the focus of Jenner’s experiments. 
However, huge challenges remain in the field of vaccine 
development. The microbes that cause infectious dis- 
eases seem to adapt more readily to the selective pressure 
applied by antimicrobial agents than to the pressure 
applied by the immune system. Moreover, new pathogens 
continually emerge, armed with novel mechanisms for 
damaging the host and evading the immune system. 
The Jenner Symposium was held in Hong Kong on 
June 10, 1996, at the 7th International Congress for Infec- 
tious Diseases. Many of the talks from the symposium 
make up this supplement. Expert authors were asked to 
review the state of the art of vaccine development or clin- 
ical trials in their fields of primary interest. The resulting 
presentations cover not only the challenging old and new 
diseases for which effective or improved vaccines are 
needed, but also the complex social and political problems 
encountered in vaccine acceptance and utilization. 
Dr. de Quadros reviews the efforts of the World 
Health Assembly to eradicate poliomyelitis by vaccina- 
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tion. As a result of these efforts, there have been no new 
cases of polio in the Americas since 1991. Dr. Gershon 
describes the historical development and the current sta- 
tus of the new live attenuated varicella vaccine. The sta- 
tus of vaccines for rabies is reviewed by Dr. Wilde. Several 
new acellular vaccines for pertussis are likely to be 
released soon, and some of these preparations are 
reviewed by Drs. Olin and Taranger and their colleagues. 
A unique strategy to overcome the lack of immuno- 
genicity of the group B meningococcal vaccine is pre- 
sented by Dr. Jennings. Dr. Granoff and his co-authors 
write about improving the immunogenicity of other 
meningococcal group polysaccharides by coupling them 
to protein carriers, an approach that was used success- 
fully in the development of the Haemophilus injluen- 
zae vaccine. Dr. McAdam discusses the potential for a 
vaccine to prevent tuberculosis-an old enemy, but also 
a prominent emerging pathogen with new antimicrobial 
resistance patterns. 
Dr. Hampson discusses the need for programs to 
deliver safe and effective vaccines to adults in order to 
prevent disease caused by the common serious respira- 
tory pathogens-influenza virus and Streptococcuspneu- 
moniae. Dr. Salisbury presents some important practical 
issues related to the actual practice of immunization, such 
as enlisting recipients and developing public acceptance 
of vaccine programs. 
In contrast to the continuing advances in the devel- 
opment of bacterial and viral vaccines, the development 
of vaccines for fungal and parasitic diseases is still in a 
rudimentary stage. Fungi and parasites employ sophisti- 
cated strategies for survival in the infected host, and 
much more basic research is necessary to develop can- 
didate vaccines. Perhaps we must await the next Jenner- 
like breakthrough that will establish a new guiding 
principle for preventing infections with these organisms. 
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